Imaging Biometrics

Dr. Max Krucoff’s use of Delta T1 maps to assess ablation extent after LITT is a powerful example of how the objective, quantitative imaging of Delta T1 maps can elevate clinical decision-making and confidence.

Unlike conventional image (like T1+C) that rely on subjective interpretation, Delta T1 maps remove ambiguity—delivering reproducible insights that support better outcomes.

Proud to see Imaging Biometrics’ technology helping clinicians push the boundaries of neuro-oncology!

x.com

Great work MCW!

Chasing Chad recently met with several doctors from the Medical College of Wisconsin to hear updates on all the great work they are doing for brain tumor patients: Gallium Maltolate (GaM) trial, Pulsed Lose Dose Radiation (PLDR) trial, researching and mapping brain functions for better surgical outcomes and creating a neuro-oncology fellowship. Thank you Drs. Connelly, Straza and Krucoff for all that you do!

https://x.com/IQAI_IB/status/1856717329742114938

x.com

Sign up for our upcoming Webinar on Accurate DSC-MRI Acquisition on April 16, 11AM, CDT!

Check out our March Newsletter!
https://mailchi.mp/imagingbiometrics/ib-newsletter-edition-17708575

We're looking forward to this upcoming event with industry leaders!

Glioblastoma Drug Development Summit | March 2024 Implementing Diverse Mechanisms Across Improved Clinical Translation to Develop Safe, Effective & Deliverable Glioblastoma Therapies

While a small study, advanced imaging proves important to Tumor Treating Fields.

NIMG-29. ADVANCED MRI BIOMARKERS PREDICT EARLY RESPONSE TO TUMOR TREATING FIELDS IN GLIOBLASTOMA AbstractBACKGROUND. Tumor-treating fields (TTFields) is a novel US FDA-approved antimitotic treatment modality for patients with newly diagnosed and recurrent g

"The utility of dT1 maps! Decreased RTV, correlates with improved OS in patients with GBM, a simple and objective means by which surgical outcomes can be routinely assessed."

Application of Delta T1 Maps for Quantitative and Objective ... : Neurosurgery Practice response, the objective of this study is to evaluate the clinical efficacy of an easy-to-use MRI metric, called delta T1 (dT1), to quantify the extent of resection (EOR) and RTV, in comparison with radiologist impression, to predict overall survival (OS) in patients with glioblastoma. METHODS: Fifty...

Here's a good research article describing the effects of Gallium Maltolate, for more information about the Expanded Access Program, or to sign up please fill out the form on our website:

Contact Us – Clinical Trials Expanded Access Program – Imaging Biometrics

Watch yesterday's Webinar to learn how IB Nimble, a mobile app, improves Healthcare outcomes!

IB Nimble, IB Users Group Webinar Jan 30 2024 Dr Bovi Dr. Joe Bovi shares the current landscape of algorithmic medicine, the history of the IB Nimble application (the handheld mobile device that enables multi-di...